NCT07015333已完成不适用
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Commonwealth Healthcare Corporation1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2020年3月1日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced betel nut-induced oral cancer
排除标准
- 未提供
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: From date first treatment received until 3 months later
Assessed by clinical measurement of largest tumor size
次要结局
未报告次要终点
研究者
Peter Brett, MD
Director, Medical Oncology
Commonwealth Healthcare Corporation
研究点 (1)
Loading locations...
相似试验
终止
2 期
Pembrolizumab in HNSCC With Residual Disease After RadiationHead and Neck Squamous Cell CarcinomaNCT02892201Yale University9
招募中
不适用
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyMarginal Zone LymphomaNCT06478472The First Affiliated Hospital of Xiamen University36
进行中（未招募）
2 期
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaNCT04643379Washington University School of Medicine30
已完成
不适用
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaNCT06771674Hookipa Biotech GmbH662
已完成
2 期
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)Esophagogastric Junction CarcinomaEsophageal CarcinomaNCT02559687Merck Sharp & Dohme LLC121